Ray Therapeutics

November 19, 2021

California Institute for Regenerative Medicine (CIRM)
1999 Harrison Street,
Suite 1650
Oakland, CA
94612

RE: Application Review Subcommittee Meeting for TRAN1-12889 Application

Dear Members of the Independent Citizens Oversight Committee,

I am leading the CMC program at Ray Therapeutics. By way of background, I have over thirty years of global experience in biologics product development from concept to market approval. In 2000 as CEO and co-founder I established a CDMO building world class biologics development and clinical manufacturing facilities before a trade sale to Watson Pharmaceuticals Inc. Most recently, as Allergan's SVP Biologics and Small Molecule R & D I had accountability for all aspects of process development managing laboratories in Irvine, Ca, Madison NJ and Liverpool UK. Relevant to Ray-001 this included leading CMC teams engaged in optogenetics and CRISPR-Cas9 viral gene therapy. During my time in Allergan I had the opportunity to meet patient advocates that exposed me to the life challenges patients face with these conditions hence I am very motivated and excited to be working with the Ray team.

Paul Bresge, CEO of Ray Therapeutics, has asked me to attend the subcommittee meeting on November 23rd to address any questions you may have regarding Ray's revised development timelines, which reflect real-time information from our CDMO partner. I understand that I will only have three minutes to speak about our current plans for Ray-001, so I thought that it would be best to provide our updated project schedule in advance. Please see the following page.

I look forward to the subcommittee meeting and hope that Ray receives funding for this important therapy.

Sincerely,

Crawford Brown, PhD
Ray Therapeutics


Activity
2021
2022
2023
2024
In Scope Activities for TRAN1
Mouse dose range/safety
NHP Safety and Biodistribution
In Vitro human retinal explant study
Future GLP Phase
CDMO Contracting
Research Grade Plasmids
Process Development
GMP Source Plasmids
Process Scale-up
Analytical Development
CDMO Audit
Tox Batch
Stability
Compatibility Studies
Process and Specification Lock
Process Confirmation Batch
Clinical Batch
Clinical Development Planning
Pre-IND prep and meeting
3-month mouse tox
6-month NHP tox
IND prep, submission
Future GLP Phase